Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

ZS Pharma: Astra Zeneca to Acquire ZS Pharma at $90 per Share-DARN (ZSPH, $90)

On Friday, November 9, 2015 Astra Zeneca entered into a definitive agreement to buy ZS Pharma in an all-cash tender…
Read more…

Comments on Antares, Agenus, Cytokinetics, Discovery Laboratories and ZS Pharma

SmithOnStocks Mailbox
April 28, 2015
A Quick Take on Recent Events
If you have a question for the mailbox, contact me.
Purpose of this…
Read more…

Initiation Report on ZS Pharma (ZSPH, Buy, $40.97, Subscribers only)

ZS Pharma Investment Thesis
The Hyperkalemia Market Opportunity is Huge; There Are No Good Current Drugs

The most important piece of the…
Read more…

Effective Treatment of Hyperkalemia Promises to be a Multi-billion Opportunity

Key Points

There are no effective treatment options for long term treatment of hyperkalemia (high potassium levels).
My research suggests that the…
Read more…